

## 51.Heart failure (pharmacology)

Abstract No.	First Name	Last Name	Program No.	Session	Session Title	Date	Time	Order	Room	Abstract Title
WORD 1	A.O.	Khalikova	PE61-8	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	8	New Hall, 1F ,Kyoto International Conference Center	EVALUATION OF CLINICAL EFFICIENCY OF SUCOBETRIL / VALSARTAN IN PATIENTS WITH CHRONIC CARDIAC INSUFFICIENCY WITH ASSOCIATED DIABETES MILLETENSUS 2 TYPE
10071	Hajime	Kataoka	PE61-3	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	3	New Hall, 1F ,Kyoto International Conference Center	Alternative diuretic of acetazolamide to vasopressin antagonists for modulation of hyponatremia in cardiovascular patients
10089	Yu	Sato	OJ24-8	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	8	Room 555, 5F ,Kyoto International Conference Center	Associations of Benzodiazepine with Adverse Prognosis in Heart Failure Patients with Insomnia
10112	Kentaro	Matsumura	OJ24-1	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	1	Room 555, 5F ,Kyoto International Conference Center	Predictive Value of Low Lymphocyte Concentration and Effectiveness of Statin in Aged Patients with Chronic Heart Failure Complicated Lymphocytopenia
10162	Kentaro	Matsumura	OJ24-5	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	5	Room 555, 5F ,Kyoto International Conference Center	Nutritional Status in Patients with Chronic Heart Failure and Availability of &omega;-3 Fatty Acids Supplements on Cardiovascular Death in Statin-non-Users
10218	Yoko	Shimizu	FRS05-4	Featured Research Session 05	Heart Failure/Cardiomyopathy	March 13 (Fri)	17:10-18:40	4	Room E, B1F ,Kyoto International Conference Center	Stabilization of CaMKII-phosphorylated RyR2 mediated through pharmacological enhancement of calmodulin binding to RyR2 prevents the development of cardiac dysfunction
10349	Yoshiaki	Kubota	OJ24-2	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	2	Room 555, 5F ,Kyoto International Conference Center	Impact of &Beta;-blocker on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease -ASIAN HF registry-
10384	Meihua	Li	OJ24-6	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	6	Room 555, 5F ,Kyoto International Conference Center	Donepezil Markedly Attenuates the Progression of Cardiac/Renal Remodeling in Rats with Renal Artery Stenosis-Induced Hypertension
10408	Mayu	Nishio	PE61-1	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	1	New Hall, 1F ,Kyoto International Conference Center	Economic Impact of Heart Failure with Preserved Ejection Fraction: Insights from the PURSUIT-HFpEF Registry
10447	Hidekatsu	Fukuta	PJ41-3	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	3	New Hall, 1F ,Kyoto International Conference Center	Effects of Renin-Angiotensin System Inhibitors on Cardiac Structure and Function in Heart Failure with Preserved/Mid-Range Ejection Fraction: A Meta-Analysis
10548	Kazuuya	Nagao	OE032-1	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	1	Room E, B1F ,Kyoto International Conference Center	Long-term Outcome of the Use of Inotropes and Vasodilators in the Contemporary Treatment of Acutely Decompensated Heart Failure
10562	Noriyuki	Ikehara	OJ24-9	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	9	Room 555, 5F ,Kyoto International Conference Center	1-hour Diuretic Response to Initial Intravenous 20mg Furosemide in Patients with Acute Decompensated Heart Failure
10664	rennosuke	Yamaguchi	PE61-6	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	6	New Hall, 1F ,Kyoto International Conference Center	Impact of Polyparmacy on Adherence and Prognosis in Patients with Acute Decompensated Heart Failure: From CURE-HF Registry
10685	Yasuhiro	Hitomi	OE031-2	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	2	Room D, 1F ,Kyoto International Conference Center	Characterization of Tolvaptan Responder and its Impact on the Outcome for Patients with Heart Failure in the Real World
10866	Shunsuke	Tamaki	PJ41-1	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	1	New Hall, 1F ,Kyoto International Conference Center	Effect of Empagliflozin as Add-on Therapy on Decongestion and Renal Function in Diabetic Patients Hospitalized for Acute Decompensated Heart Failure
10942	Ayako	Harima	OE032-2	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	2	Room E, B1F ,Kyoto International Conference Center	Eosinophilia during the treatment of heart failure with using cardiotonic drugs
10954	Tomoyuki	Hamada	OJ24-4	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	4	Room 555, 5F ,Kyoto International Conference Center	Age Difference in Clinical Impact of Guideline-Directed Medical Therapy in Patients with Acute Decompensated Heart Failure: Kochi YOSACOI Study
11007	Shuko	Iwata	PE61-4	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	4	New Hall, 1F ,Kyoto International Conference Center	Title Effectiveness and Safety of Tolvaptan in Patients with Acute Heart Failure Prior to Long-distance Transfer
11017	Neiko	Ozasa	OE032-4	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	4	Room E, B1F ,Kyoto International Conference Center	The impact of multiple medications on long-term prognosis in patients with acute decompensated HF-insights from the KCHF registry

**51.Heart failure (pharmacology)**

Abstract No.	First Name	Last Name	Program No.	Session	Session Title	Date	Time	Order	Room	Abstract Title
11153	Akihiro	Nakagomi	OE006-5	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	5	Room D, 1F ,Kyoto International Conference Center	Effects of Eicosapentaenoic Acid on the Monocyte Tissue Factor Activity and Long-Term Prognosis in Chronic Heart Failure Patients with Hypertriglyceridemia
11190	Kimiko	Nagara	OE006-6	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	6	Room D, 1F ,Kyoto International Conference Center	Impact of Target Heart Rate in Heart Failure Patients with Beta-blocker Treatment
11202	Toru	Miyoshi	OE032-3	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	3	Room E, B1F ,Kyoto International Conference Center	Efficacy of digitalis on heart failure with reduced ejection fraction and sinus tachycardia under administration of more than two catecholamines
11211	Wataru	Takahashi	PJ41-6	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	6	New Hall, 1F ,Kyoto International Conference Center	Clinical Effects of Carvedilol to Systolic Heart Failure with Atrial Fibrillation by Left Ventricular Ejection Fraction
11259	Masafumi	Kitakaze	OJ24-3	一般演題口述 (日本語) 24	Heart failure (Pharmacotherapy) 2	March 13 (Fri)	17:15-18:45	3	Room 555, 5F ,Kyoto International Conference Center	The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure Trial (DAPA-HF)
11268	Masayuki	Gotou	OE032-6	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	6	Room E, B1F ,Kyoto International Conference Center	Morphine Use during Palliative Care for Patients with Chronic Heart Failure
11280	Sho	Suzuki	OE006-1	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	1	Room D, 1F ,Kyoto International Conference Center	Association of mineralocorticoid receptor antagonist use and cardiovascular events in patients with heart failure with preserved ejection fraction.
11390	Yuta	Watanabe	OE031-1	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	1	Room D, 1F ,Kyoto International Conference Center	The Incidence of Worsening Renal Failure on Long-Term Use of Tolvaptan in Patients With Congestive Heart Failure
11403	Sho	Suzuki	PE61-7	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	7	New Hall, 1F ,Kyoto International Conference Center	Association of early tolvaptan treatment and length of hospital stay in elderly patients with heart failure with preserved ejection fraction.
11414	Juri	Kawaguchi	OE032-5	Oral Presentation(English) 032	Heart failure (Pharmacotherapy) 3	March 12 (Thu)	14:25-15:25	5	Room E, B1F ,Kyoto International Conference Center	Real-world practice of morphine therapy for refractory dyspnea in end-stage chronic heart failure patients
11432	Makoto	Takeuchi	PJ31-8	ポスターセッション(日本語)31	Heart failure (risk factors)	March 14 (Sat), 2020	17:10-18:06	8	New Hall, 1F ,Kyoto International Conference Center	Female Gender, Heart Rate and Early Drop in Systolic Blood Pressure: Associations with Renal Function in the Elderly with HFREF
11737	Hidetada	Fukuoka	PJ41-2	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	2	New Hall, 1F ,Kyoto International Conference Center	Risk factors for hyponatremia in patients with acute decompensated heart failure treated with tolvaptan during early phase
11774	Yusuke	Morita	PE61-5	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	5	New Hall, 1F ,Kyoto International Conference Center	Clinical Effectiveness and Adverse Events of Tolvaptan in Very Elderly Patients with Acute Decompensated Heart Failure
11809	Takuro	Abe	OE006-3	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	3	Room D, 1F ,Kyoto International Conference Center	Additional Mineralocorticoid-receptor Antagonist Improves Cardiovascular Mortality in Heart Failure Patients with Insufficient Doses of Guideline-recommended Medication: Propensity-score Matching Analysis
11849	Shota	Shirovani	OE031-5	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	5	Room D, 1F ,Kyoto International Conference Center	Observational Report of the Prognostic Impact of Landiolol in Acute Heart Failure Patients Presenting Atrial Fibrillation with Rapid Ventricular Response
11928	Masaki	Nakagaito	PJ41-7	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	7	New Hall, 1F ,Kyoto International Conference Center	Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients with Type 2 Diabetes
12022	Masaki	Nakagaito	PJ41-4	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	4	New Hall, 1F ,Kyoto International Conference Center	Comparison of SGLT2 Inhibitors Induced Diuretic Action in Diabetic Patients with Heart Failure with Reduced, Midrange And Preserved Ejection Fraction
12228	Aiko	Takami	OE031-3	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	3	Room D, 1F ,Kyoto International Conference Center	Blood Urea Nitrogen and Hematocrit Predict the Therapeutic Response to Low-dose Tolvaptan in Patients with Heart Failure
12243	Takemi	Handa	PJ41-5	ポスターセッション(日本語)41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	5	New Hall, 1F ,Kyoto International Conference Center	Outpatient Use of Tolvaptan Extended a Period until Recurrence Heart Failure Admission in Patients Over 85 Years Old.

## 51.Heart failure (pharmacology)

Abstract No.	First Name	Last Name	Program No.	Session	Session Title	Date	Time	Order	Room	Abstract Title
12274	Yanagawa	Kyosuke	OE006-4	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	4	Room D, 1F ,Kyoto International Conference Center	Beneficial Effect of Exchanging Dipeptidyl Peptidase 4 Inhibitor for Canagliflozin on Heart Failure with Diabetes Mellitus: CHANGE trial
12355	Atomu	Tajima	OE031-4	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	4	Room D, 1F ,Kyoto International Conference Center	Impact of Tolvaptan on Fluid Management in Heart Failure Patients with Cardiac Amyloidosis
12633	Satoshi	Oka	OE031-6	Oral Presentation(English) 031	Heart failure (Pharmacotherapy) 1	March 12 (Thu)	15:30-16:30	6	Room D, 1F ,Kyoto International Conference Center	Effects of Sodium-Glucose Co-Transporter 2 Inhibitor on Left Ventricular Function in Heart Failure Patients with Type 2 Diabetes Mellitus
12749	Akiko	Yoshimoto	PJ41-8	ポスターセッション(日本語) 41	Heart failure (Pharmacotherapy) 2	March 15 (Sun)	15:10-16:06	8	New Hall, 1F ,Kyoto International Conference Center	Utilization of Codeine for Heart Failure Patients with Breathlessness in Home Palliative Care.
20009	Abdallah	Almaghraby	OE006-2	Oral Presentation(English) 006	Heart failure (Neurohormonal and metabolic modulation)	March 12 (Thu)	09:45-10:45	2	Room D, 1F ,Kyoto International Conference Center	The Impact of the Use of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients
20133	wei tsung	Wu	PE61-2	Poster Session (English) 61	Heart failure (Pharmacotherapy) 1	March 15 (Sun)	14:10-15:06	2	New Hall, 1F ,Kyoto International Conference Center	Prescription Pattern of Angiotensin Receptor Nephilysin Inhibition Is Associated with Heart Failure Events